Show simple item record

dc.contributor.authorDuffy, SW
dc.contributor.authorTabár, L
dc.contributor.authorYen, AM-F
dc.contributor.authorDean, PB
dc.contributor.authorSmith, RA
dc.contributor.authorJonsson, H
dc.contributor.authorTörnberg, S
dc.contributor.authorChiu, SY-H
dc.contributor.authorChen, SL-S
dc.contributor.authorJen, GH-H
dc.contributor.authorKu, MM-S
dc.contributor.authorHsu, C-Y
dc.contributor.authorAhlgren, J
dc.contributor.authorMaroni, R
dc.contributor.authorHolmberg, L
dc.contributor.authorChen, TH-H
dc.date.accessioned2021-04-15T18:49:17Z
dc.date.available2021-04-15T18:49:17Z
dc.date.issued2021-03-02
dc.identifier.issn1527-1315
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/71297
dc.description.abstractBackground Previously, the risk of death from breast cancer was analyzed for women participating versus those not participating in the last screening examination before breast cancer diagnosis. Consecutive attendance patterns may further refine estimates. Purpose To estimate the effect of participation in successive mammographic screening examinations on breast cancer mortality. Materials and Methods Participation data for Swedish women eligible for screening mammography in nine counties from 1992 to 2016 were linked with data from registries and regional cancer centers for breast cancer diagnosis, cause, and date of death (Uppsala University ethics committee registration number: 2017/147). Incidence-based breast cancer mortality was calculated by whether the women had participated in the most recent screening examination prior to diagnosis only (intermittent participants), the penultimate screening examination only (lapsed participants), both examinations (serial participants), or neither examination (serial nonparticipants). Rates were analyzed with Poisson regression. We also analyzed incidence of breast cancers proving fatal within 10 years. Results Data were available for a total average population of 549 091 women (average age, 58.9 years ± 6.7 [standard deviation]). The numbers of participants in the four groups were as follows: serial participants, 392 135; intermittent participants, 41 746; lapsed participants, 30 945; and serial nonparticipants, 84 265. Serial participants had a 49% lower risk of breast cancer mortality (relative risk [RR], 0.51; 95% CI: 0.48, 0.55; P < .001) and a 50% lower risk of death from breast cancer within 10 years of diagnosis (RR, 0.50; 95% CI: 0.46, 0.55; P < .001) than serial nonparticipants. Lapsed and intermittent participants had a smaller reduction. Serial participants had significantly lower risk of both outcomes than lapsed or intermittent participants. Analyses correcting for potential biases made little difference to the results. Conclusion Women participating in the last two breast cancer screening examinations prior to breast cancer diagnosis had the largest reduction in breast cancer death. Missing either one of the last two examinations conferred a significantly higher risk. © RSNA, 2021 Online supplemental material is available for this article.en_US
dc.format.extent203935
dc.languageeng
dc.publisherRadiological Society of North Americaen_US
dc.relation.ispartofRadiology
dc.rightsPublished under a CC BY 4.0 license.
dc.titleBeneficial Effect of Consecutive Screening Mammography Examinations on Mortality from Breast Cancer: A Prospective Study.en_US
dc.typeArticleen_US
dc.identifier.doi10.1148/radiol.2021203935
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/33650900en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.publisher-urlhttp://doi.org/10.1148/radiol.2021203935
dcterms.dateAccepted2021-01-12
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record